Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 249

1.

Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study.

Blaha MJ, Budoff MJ, DeFilippis AP, Blankstein R, Rivera JJ, Agatston A, O'Leary DH, Lima J, Blumenthal RS, Nasir K.

Lancet. 2011 Aug 20;378(9792):684-92. doi: 10.1016/S0140-6736(11)60784-8.

PMID:
21856482
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Trial Study Group.

Lancet. 2009 Apr 4;373(9670):1175-82. doi: 10.1016/S0140-6736(09)60447-5. Epub 2009 Mar 28.

PMID:
19329177
[PubMed - indexed for MEDLINE]
3.

Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).

Ridker PM, MacFadyen JG, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group.

Circ Cardiovasc Qual Outcomes. 2009 Nov;2(6):616-23. doi: 10.1161/CIRCOUTCOMES.109.848473. Epub 2009 Sep 22.

PMID:
20031900
[PubMed - indexed for MEDLINE]
Free Article
4.

Polypill therapy, subclinical atherosclerosis, and cardiovascular events-implications for the use of preventive pharmacotherapy: MESA (Multi-Ethnic Study of Atherosclerosis).

Bittencourt MS, Blaha MJ, Blankstein R, Budoff M, Vargas JD, Blumenthal RS, Agatston AS, Nasir K.

J Am Coll Cardiol. 2014 Feb 11;63(5):434-43. doi: 10.1016/j.jacc.2013.08.1640. Epub 2013 Oct 23.

PMID:
24161320
[PubMed - indexed for MEDLINE]
5.

Clinical implications of JUPITER in a contemporary European population: the EPIC-Norfolk prospective population study.

Sondermeijer BM, Boekholdt SM, Rana JS, Kastelein JJ, Wareham NJ, Khaw KT.

Eur Heart J. 2013 May;34(18):1350-7. doi: 10.1093/eurheartj/eht047. Epub 2013 Feb 28.

PMID:
23449857
[PubMed - indexed for MEDLINE]
Free Article
6.

Association between obesity, high-sensitivity C-reactive protein ≥2 mg/L, and subclinical atherosclerosis: implications of JUPITER from the Multi-Ethnic Study of Atherosclerosis.

Blaha MJ, Rivera JJ, Budoff MJ, Blankstein R, Agatston A, O'Leary DH, Cushman M, Lakoski S, Criqui MH, Szklo M, Blumenthal RS, Nasir K.

Arterioscler Thromb Vasc Biol. 2011 Jun;31(6):1430-8. doi: 10.1161/ATVBAHA.111.223768. Epub 2011 Apr 7.

PMID:
21474823
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.

Kones R.

Drug Des Devel Ther. 2011;5:325-80. doi: 10.2147/DDDT.S14934. Epub 2011 Jun 13. Review.

PMID:
21792295
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.

Carter NJ.

Am J Cardiovasc Drugs. 2010;10(6):383-400. doi: 10.2165/11204600-000000000-00000. Review.

PMID:
21090831
[PubMed - indexed for MEDLINE]
10.

Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis.

Martin SS, Blaha MJ, Blankstein R, Agatston A, Rivera JJ, Virani SS, Ouyang P, Jones SR, Blumenthal RS, Budoff MJ, Nasir K.

Circulation. 2014 Jan 7;129(1):77-86. doi: 10.1161/CIRCULATIONAHA.113.003625. Epub 2013 Oct 20.

PMID:
24141324
[PubMed - indexed for MEDLINE]
11.

Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study.

Glynn RJ, MacFadyen JG, Ridker PM.

Clin Chem. 2009 Feb;55(2):305-12. doi: 10.1373/clinchem.2008.120642. Epub 2008 Dec 18.

PMID:
19095726
[PubMed - indexed for MEDLINE]
Free Article
12.
13.

Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective.

Kones R.

Drug Des Devel Ther. 2010 Dec 9;4:383-413. doi: 10.2147/DDDT.S10812. Review.

PMID:
21267417
[PubMed - indexed for MEDLINE]
Free PMC Article
14.
15.

Estimating treatment effects for individual patients based on the results of randomised clinical trials.

Dorresteijn JA, Visseren FL, Ridker PM, Wassink AM, Paynter NP, Steyerberg EW, van der Graaf Y, Cook NR.

BMJ. 2011 Oct 3;343:d5888. doi: 10.1136/bmj.d5888.

PMID:
21968126
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial.

Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM.

Ann Intern Med. 2010 Apr 20;152(8):488-96, W174. doi: 10.7326/0003-4819-152-8-201004200-00005.

PMID:
20404379
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.

Stewart RA.

Future Cardiol. 2009 May;5(3):231-6. doi: 10.2217/fca.09.8.

PMID:
19656039
[PubMed - indexed for MEDLINE]
18.

A tale of three labels: translating the JUPITER trial data into regulatory claims.

Ridker PM.

Clin Trials. 2011 Aug;8(4):417-22. doi: 10.1177/1740774511407939.

PMID:
21835857
[PubMed - indexed for MEDLINE]
19.

The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial.

Novack V, MacFadyen J, Malhotra A, Almog Y, Glynn RJ, Ridker PM.

CMAJ. 2012 Apr 17;184(7):E367-72. doi: 10.1503/cmaj.111017. Epub 2012 Mar 19.

PMID:
22431901
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Coronary artery calcium scores and risk for cardiovascular events in women classified as "low risk" based on Framingham risk score: the multi-ethnic study of atherosclerosis (MESA).

Lakoski SG, Greenland P, Wong ND, Schreiner PJ, Herrington DM, Kronmal RA, Liu K, Blumenthal RS.

Arch Intern Med. 2007 Dec 10;167(22):2437-42.

PMID:
18071165
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk